Pharmamotion has now a new page containing updates on clopidogrel PPI interactions.
According to the results of the COGENT trial, the combination of the antiplatelet clopidogrel and the PPI omeprazole does not produce clinically relevant cardiovascular interactions. The investigators also suggest that prophylactic PPIs seem to be a very promising strategy to reduce GI events in patients on antithrombotic therapy.
These results were presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
Also of clinical importance: prasugrel was approved this year for prevention of atherothrombotic events in patients with acute coronary syndromes undergoing primary or delayed percutaneous coronary intervention (PCI).
Further reading
COGENT: No CV events but significant GI benefits of PPI omeprazole. TheHeart.org